Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
December 05 2016 - 8:00AM
Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical
company advancing novel, adeno-associated virus (AAV) gene
therapies targeting the liver, a key organ for human metabolism,
today announced an oral poster presentation that highlights
findings of in vivo preclinical studies demonstrating that the
selection of capsid, a key component of AAV vectors, can enhance
product efficiency and potentially reduce host immune responses to
therapy. The presentation took place during the 58th American
Society of Hematology (ASH) Annual Meeting, which is being held in
San Diego, California, December 3-6, 2016.
In the poster, titled “Strategies for Selection of
AAV Vectors for Administration to Liver: Studies in Nonhuman
Primates” (Abstract # 2316), researchers at the University of
Pennsylvania (Penn) and Dimension are reporting that capsid
serotypes AAV8 and AAVrh10, both members of the Clade E AAV family,
result in higher levels of gene transfer to the primate liver than
other vectors, including AAV5 and AAV3B. In addition, the choice of
capsid can result in reduced production of neutralizing antibodies
as part of the host immune response and potentially limit immune
responses to follow-on administration of a second vector.
“We are pleased to announce key findings from our
highly productive collaboration with Penn and the lab of James
Wilson, MD, PhD, a professor of Medicine and Pediatrics in the
Perelman School of Medicine at Penn,” said Dr. Annalisa Jenkins,
MBBS, FRCP, Chief Executive Officer of Dimension. “These data
add to the body of science supporting Dimension’s choice of the
Clade E family of capsid serotypes for programs where the liver is
the primary target organ.”
Penn, Wilson, and Wadsworth are each holders of
Dimension stock, and Wilson also holds stock in REGENXBIO, Inc.
Dimension holds exclusive sublicenses from REGENXBIO, Inc. for
certain Penn-owned AAV technologies related to this development
program and has an ongoing research collaboration and licensing
relationship with Penn.
About Dimension Therapeutics,
Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) is the
leader in discovering and developing new therapeutic products for
people living with devastating rare and metabolic diseases
associated with the liver, based on the most advanced, mammalian
adeno-associated virus (AAV) gene delivery technology. Dimension is
actively progressing its broad pipeline, which features programs
addressing unmet needs for patients suffering from inherited
metabolic diseases, including OTC deficiency, GSDIa, citrullinemia
type 1, PKU, Wilson disease, a collaboration with Bayer in
hemophilia A, and a wholly owned clinical program in hemophilia B.
The company targets diseases with readily identifiable patient
populations, highly predictive preclinical models, and
well-described, and often clinically validated, biomarkers. Founded
in 2013, Dimension maintains headquarters in Cambridge,
Massachusetts.
For more information, please visit
www.dimensiontx.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including, but not limited to, statements
regarding development, preclinical results, and the continued
progress of Dimension’s portfolio and program. All such
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include
the risks that Dimension’s product candidates, including its lead
candidate, DTX101, will not successfully be developed or
commercialized; and the risks described under the caption "Risk
Factors" in Dimension Therapeutics’ Quarterly Report on Form 10-Q
for the quarter ended September 30, 2016, which is on file with the
Securities and Exchange Commission, as well as other risks detailed
in Dimension Therapeutics’ additional filings with the Securities
and Exchange Commission. All information in this press release is
as of the date of the release, and Dimension Therapeutics
undertakes no duty to update this information unless required by
law.
Jean Franchi
Chief Financial Officer
Dimension Therapeutics
617-714-0709
jean.franchi@dimensiontx.com
Burns McClellan, on behalf of Dimension Therapeutics
Media: Justin Jackson
212-213-0006, ext.327
jjackson@burnsmc.com
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
DIMENSION THERAPEUTICS, INC. (NASDAQ:DMTX)
Historical Stock Chart
From Sep 2023 to Sep 2024